High-dose concurrent chemo-proton therapy for Stage III NSCLC: Preliminary results of a Phase II study

Journal of Radiation Research

Volumn 55, Issue 5, 2014, Pages 959-965

  Oshiro, Yoshiko ^a   Okumura, Toshiyuki ^a   Kurishima, Koichi ^a   Homma, Shinsuke ^a   Mizumoto, Masashi ^a   Ishikawa, Hitoshi ^a   Onizuka, Masataka ^a   Sakai, Mitsuaki ^a   Goto, Yukinobu ^a   Hizawa, Nobuyuki ^a   Sato, Yukio ^a   Sakurai, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

chemo proton therapy; lung cancer; Phase II study; proton therapy; radiotherapy

Indexed keywords

BIOLOGICAL ORGANS; BODY FLUIDS; CHEMOTHERAPY; DISEASES; PROTON BEAMS; RADIOTHERAPY;

CHEMO-PROTON THERAPY; CONCURRENT CHEMOTHERAPY; HIGH DOSE; LUNG CANCER; NON SMALL CELL LUNG CANCER; PHASE II; PHASE II STUDY; PROTON THERAPY; STAGE III;

PROTON BEAM THERAPY;

ANTINEOPLASTIC AGENT; CISPLATIN; NAVELBINE; PROTON; VINBLASTINE;

ADULT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MEGAVOLTAGE RADIOTHERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROCEDURES; RADIATION DOSE; RADIATION INJURIES; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROTONS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; TREATMENT OUTCOME; VINBLASTINE;

EID: 84908206918     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rru034     Document Type: Article

References (20)

1. Blackstock AW, Ho C, Butler J et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 2006;1:434-40.
2. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-36.
3. Socinski MA, Morris D E, Halle JS et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004;22: 4341-50.
4. Socinski M.A.,Rosenman JG,Halle J,et al., Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung car cinoma: a modified phase I/II trial, Cancer, 2001, 92, 1213-23.
5. Socinski MA, Blackstock AW, Bogart JA et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherap y and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-63.
6. Rosenman JG, Halle JS, Socinski MA et al. High- dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-56.
7. Bradley JD, Paulus R, Komaki R et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy ± cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary fin dings on radiation dose in RTOG 0617. Abstracts of the Fifty-third Annual Meeting of the American Society for Radiation Oncology, Miami, 2011.
8. Cox JD. Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 2012;82:1042-4.
9. Shioyama Y, Tokuuye K, Okumura T et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:7-13.
10. Oshiro Y, Mizumoto M, Okumura T et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2012;7:370-5.
11. Nakayama H, Satoh H, Sugahara S et al. Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;81:979-84.
12. P aganetti H, Niemierko A, Ancukiewicz M et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 2002;53:407-21.
13. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13: 176-81.
14. James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-8.
15. Roelofs E, Engelsman M, Rasch C et al. Results of a mul ticentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012;7:165-76.
16. Nichols RC, Huh SN, Henderson RH et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 2011;12:252-7.
17. Chang JY, Komaki R, Lu C et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011;117: 4707- 13.
18. Hoppe BS, Flampouri S, Henderson RH et al. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. Clin Lung Cancer 2012;13:352-8.
19. Vokes EE, Herndon JE, II, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-sm all-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8.
20. Sekine I, Nokihara H, Sumi M et al. Docetaxel consolidation therapy following cisplatin, vinorelbine , and concurrent thoracic radiotherapy in patients with unresectable stage III nonsmall cell lung cancer. J Thorac Oncol 2006;1:810-5.